TD Cowen maintains BridgeBio Pharma at Buy, lowers price target to $100 from $110
TD Cowen kept its Buy rating on BridgeBio Pharma but reduced its price target to $100 from $110, a 9.1% cut. This implies a 41.4% upside from the Oct 29 closing price of $70.73. Recent analyst targets for the stock range from $88 to $156.
How this was made

The 30-second read
Why it matters
The target cut may trigger short-term selling pressure but long-term investors may wait for trial outcomes.
Market read
Analyst target adjustments are a key driver for biotech stock movements, especially for small-cap companies.
What to watch
Upcoming clinical trial data could offset the target reduction if results are positive.
Background
BridgeBio Pharma is a clinical-stage biotech focused on rare diseases; analyst coverage influences its valuation.
Ticker impact
TD Cowen lowered BridgeBio Pharma's price target to $100 from $110.
likely pressure as the market prices in the lower target
Target reduction signals weaker outlook, prompting sellers.
Market effects
Potentially drags other biotech stocks as analysts reassess valuations.
U.S. biotech sector may see modest pullback.
Limited to investors tracking BridgeBio and comparable biotech peers.
Counterpoint
Some investors may view the cut as an entry point if they believe the market overreacted.
Key entities
- AnalystTD Cowen
Equity research firm providing the price target update.
- CompanyBridgeBio Pharma
Biotech firm whose stock is affected by the target change.



